专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011041319A3 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
公开(公告)号：WO2011041319A3
公开(公告)日：2011-06-30
申请号：PCT/US2010050559
申请日：2010-09-28
申请人： LUDWIG INST CANCER RES , OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
发明人： OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
IPC分类号： A61K51/10 , A61P35/00 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

2. 发明申请

WO2009023266A1 GENERATION OF ANTIBODIES TO CELL-SURFACE RECEPTORS AND CANCER-ASSOCIATED PROTEINS INCLUDING EGFR FAMILY MEMBERS 审中-公开
标题翻译：产生抗细胞表面受体和癌基因相关蛋白，包括EGFR家族成员
公开(公告)号：WO2009023266A1
公开(公告)日：2009-02-19
申请号：PCT/US2008/009772
申请日：2008-08-14
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , BURGESS, Antony , GARRETT, Thomas
发明人： BURGESS, Antony , GARRETT, Thomas
IPC分类号： C07K14/71 , A61K39/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/3053 , C07K16/3069 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates generally to the generation of antibodies to cell-surface receptors and cancer-associated proteins, and particularly to such receptors or proteins with cysteine rich regions or cysteine loops. Cell-surface receptors and cancer-associated proteins with cysteine rich regions or cysteine loops and suitable in this invention include EGFR and EGFR family members, insulin receptor, and tyrosine kinases such as IGFR, Ret and Ror. A method is provided generally for the generation of modulators or binders, including antibodies, to cancer associated proteins, particularly cell-surface receptors, which may, particularly in cancers or on amplification or overexpression or other tumorigenic states, display epitopes not necessarily available in correctly folded and processed proteins (wild type or normal situations). Mutant or modified such receptors or proteins, wherein the cysteine rich regions or cysteine loops are altered, or wherein the conformation of the receptor or protein is altered, serve as targets for isolating or screening modulators, including as epitopes for generating antibodies, particularly antibodies which prefer or are specific for a cancer-associated or tumorigenic form(s) of the protein or receptor. The invention also relates to the use of the altered cell-surface receptors or cancer-associated proteins in generating modulators including antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the altered cell-surface receptors or cancer-associated proteins, including EGFR and EGFR family members.
摘要翻译：本发明一般涉及产生针对细胞表面受体和癌症相关蛋白的抗体，特别涉及具有富含半胱氨酸的区域或半胱氨酸环的此类受体或蛋白质。具有半胱氨酸富集区或半胱氨酸环并且适用于本发明的细胞表面受体和癌症相关蛋白包括EGFR和EGFR家族成员，胰岛素受体和酪氨酸激酶，例如IGFR，Ret和Ror。提供了一般用于产生癌症相关蛋白质，特别是细胞表面受体的调节剂或粘合剂（包括抗体）的方法，特别是在癌症或扩增或过度表达或其他致瘤状态下，显示未必正确可用的表位折叠和加工的蛋白质（野生型或正常情况）。突变或修饰的这样的受体或蛋白质，其中改变半胱氨酸富集区或半胱氨酸环，或其中改变受体或蛋白质的构象，用作分离或筛选调节剂的靶标，包括作为产生抗体的表位，特别是抗体优选或对蛋白质或受体的癌症相关或致瘤性形式是特异性的。本发明还涉及改变的细胞表面受体或癌相关蛋白在产生包含具有抗肿瘤或抗癌活性或刺激免疫应答的抗体的调节剂中的用途。本发明还涉及特异性针对改变的细胞表面受体或癌相关蛋白（包括EGFR和EGFR家族成员）的抗体。

3. 发明申请

WO2012003544A1 PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT 审中-公开
标题翻译：蛋白激酶抑制剂和治疗方法
公开(公告)号：WO2012003544A1
公开(公告)日：2012-01-12
申请号：PCT/AU2011/000858
申请日：2011-07-08
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , LUDWIG INSTITUTE FOR CANCER RESEARCH LIMITED , LESSENE, Guillaume Laurent , BAELL, Jonathan Bayldon , BURGESS, Antony Wilks , MARUTA, Hiroshi
发明人： LESSENE, Guillaume Laurent , BAELL, Jonathan Bayldon , BURGESS, Antony Wilks , MARUTA, Hiroshi
IPC分类号： C07D487/04 , A61K31/519 , A61P29/00 , A61P19/02 , A61P35/00 , A61P35/02 , C07D231/38
CPC分类号： C07D487/04 , A61K31/519
摘要： The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
摘要翻译：本发明涉及式（I）的化合物及其使用和制备方法。特别地，本发明涉及可用于治疗增殖性疾病的取代的吡唑并[3,4-d]嘧啶基化合物，在治疗方法和制备药物中使用这些化合物以及含有这些化合物的组合物。

4. 发明申请

WO1997008189A1 COLON CELL AND COLON CANCER CELL ASSOCIATED NUCLEIC ACID MOLECULES, PROTEIN AND PEPTIDES 审中-公开
标题翻译：结肠癌细胞和结肠癌细胞相关的核酸分子，蛋白质和肽
公开(公告)号：WO1997008189A1
公开(公告)日：1997-03-06
申请号：PCT/US1996012699
申请日：1996-08-05
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , WELT, Sydney , RITTER, Gerd , SIMPSON, Richard, J. , NICE, Edouard , MORITZ, R., L. , CATIMEL, Bruno , JI, Hung , BURGESS, Antony , HEATH, Joan , WHITE, Sara , JOHNSTON, Cameron , OLD, Lloyd, J.
发明人： LUDWIG INSTITUTE FOR CANCER RESEARCH
IPC分类号： C07K01/00
CPC分类号： C07K16/3046 , C07K14/47 , C07K14/705
摘要： This invention relates to isolated protein and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.
摘要翻译：本发明涉及分离的蛋白质和在结肠细胞和结肠癌细胞的表面上发现的肽，以及编码所述蛋白质和肽的核酸分子。蛋白质和肽结合肿瘤相关抗体，如mAb A33。单体蛋白质在非还原条件下通过SDS凝胶电泳测定的分子量为约43kD。此外，本发明涉及在诊断，筛选和治疗方法中所述核酸分子，蛋白质，单体或多聚体形式以及所述肽的抗体的用途。本发明还涉及以单体或多聚体形式对所述蛋白质特异性的抗体以及针对所述肽的抗体。

5. 发明申请

WO2012135360A1 BINDING PROTEINS SPECIFIC FOR EGFR EXPRESSED ON TUMOR AND USES THEREOF 审中-公开
标题翻译：特异性表达肿瘤的EGFR及其用途的结合蛋白
公开(公告)号：WO2012135360A1
公开(公告)日：2012-10-04
申请号：PCT/US2012/030971
申请日：2012-03-28
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , JOHNS, Terrance Grant , SCOTT, Andrew Mark , RITTER, Gerd , JUNGBLUTH, Achim , STOCKERT, Elizabeth , COLLINS, Vincent Peter , CAVENEE, Webster K. , HUANG, Huei-Jen Su , BURGESS, Antony Wilks , NICE, Edouard Collins , MURRAY, Anne , MARK, George , OLD, Lloyd J. , REILLY, Edward B. , PHILLIPS, Andrew C. , MEULBROEK, Jonathan A. , BUCHANAN, Fritz G.
发明人： JOHNS, Terrance Grant , SCOTT, Andrew Mark , RITTER, Gerd , JUNGBLUTH, Achim , STOCKERT, Elizabeth , COLLINS, Vincent Peter , CAVENEE, Webster K. , HUANG, Huei-Jen Su , BURGESS, Antony Wilks , NICE, Edouard Collins , MURRAY, Anne , MARK, George , OLD, Lloyd J. , REILLY, Edward B. , PHILLIPS, Andrew C. , MEULBROEK, Jonathan A. , BUCHANAN, Fritz G.
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , A61K51/10
CPC分类号： A61K39/3955 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/2863 , C07K16/30 , C07K16/4241 , C07K16/4258 , C07K16/4266 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

6. 发明申请

WO2012054978A1 NOVEL ANTI-CANCER AGENTS 审中-公开
标题翻译：新型抗癌剂
公开(公告)号：WO2012054978A1
公开(公告)日：2012-05-03
申请号：PCT/AU2011/001376
申请日：2011-10-27
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LIMITED , THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , BURGESS, Antony Wilks , WALKER, Francesca , WATSON, Keith Geoffrey , WITCHARD, Helen , LESSENE, Guillaume
发明人： BURGESS, Antony Wilks , WALKER, Francesca , WATSON, Keith Geoffrey , WITCHARD, Helen , LESSENE, Guillaume
IPC分类号： C07D403/12 , A61K31/53 , A61P35/00
CPC分类号： C07D403/12 , A61K31/53
摘要： The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的衍生物，其盐或前药。还提供了一种治疗患者癌症的方法，包括向所述受试者施用有效量的式（I）化合物或其药学上可接受的衍生物，盐或前药。还提供式（I）化合物或其药学上可接受的衍生物，盐或前药在制备用于治疗癌症的药物中的用途。此外，本发明还提供包含式（I）化合物或其药学上可接受的衍生物，其盐或前药的药物组合物。

7. 发明申请

WO2011041319A8 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：特异性结合蛋白及其用途
公开(公告)号：WO2011041319A8
公开(公告)日：2011-10-06
申请号：PCT/US2010050559
申请日：2010-09-28
申请人： LUDWIG INST FOR CANCER RES LTD , OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
发明人： OLD LLOYD J , JOHNS TERRANCE GRANT , PANOUSIS CON , SCOTT ANDREW MARK , RENNER CHRISTOPH , JUNGBLUTH ACHIM , STOCKERT ELIZABETH , COLLINS PETER , CAVENEE WEBSTER K , HUANG HUEI-JEN SU , BURGESS ANTONY WILKS , NICE EDOUARD COLLINS , MURRAY ANNE , MARK GEORGE , RITTER GERD
IPC分类号： A61K51/10 , A61P35/00 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2863 , A61K39/39558 , A61K51/103 , A61K51/1045 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/30 , C07K16/4266 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及与扩增的表皮生长因子受体（EGFR）结合并与EGFR的de2-7 EGFR截短结合的特异性结合成员，特别是抗体及其片段。具体而言，特异性结合成员识别的表位，特别是抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员还可以与化学治疗剂或抗癌剂和/或其他抗体或其片段组合用于治疗。

8. 发明申请

WO2010096434A2 SPECIFIC BINDING PROTEINS AND USES THEREOF 审中-公开
标题翻译：特异性结合蛋白及其用途
公开(公告)号：WO2010096434A2
公开(公告)日：2010-08-26
申请号：PCT/US2010/024407
申请日：2010-02-17
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , OLD, Lloyd J. , JONHS, Terrance, Grant , PANOUSIS, Con , SCOTT, Andrew, Mark , RENNER, Christoph , RITTER, Gerd , JUNGBLUTH, Achim , STOCKERT, Elizabeth , COLLINS, Peter , CAVENEE, Webster, K. , HUANG, Huei-Jen Su , BURGESS, Antony Wilks , NICE, Edouard, Collins , MURRAY, Anne , MARK, George
发明人： OLD, Lloyd J. , JONHS, Terrance, Grant , PANOUSIS, Con , SCOTT, Andrew, Mark , RENNER, Christoph , RITTER, Gerd , JUNGBLUTH, Achim , STOCKERT, Elizabeth , COLLINS, Peter , CAVENEE, Webster, K. , HUANG, Huei-Jen Su , BURGESS, Antony Wilks , NICE, Edouard, Collins , MURRAY, Anne , MARK, George
IPC分类号： C07K16/28
CPC分类号： C07K16/40 , A61K31/495 , A61K39/39541 , A61K39/39558 , A61K47/6871 , A61K51/103 , A61K51/1045 , A61K51/1078 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/30 , C07K16/4258 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是其抗体及其片段。特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。这些特异性结合成员可用于癌症的诊断和治疗。本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

9. 发明申请

WO2009023265A1 MONOCLONAL ANTIBODY 175 TARGETING THE EGF RECEPTOR AND DERIVATIVES AND USES THEREOF 审中-公开
标题翻译：单克隆抗体175指导EGF受体及其衍生物及其用途
公开(公告)号：WO2009023265A1
公开(公告)日：2009-02-19
申请号：PCT/US2008/009771
申请日：2008-08-14
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , JOHNS, Terrance, Grant , SCOTT, Andrew, Mark , BURGESS, Antony, Wilks , OLD, Llyod, J.
发明人： JOHNS, Terrance, Grant , SCOTT, Andrew, Mark , BURGESS, Antony, Wilks , OLD, Llyod, J.
IPC分类号： C07K16/28 , G01N33/50 , G01N33/574 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号： A61K45/06 , A61K39/395 , A61K2039/505 , C07K16/2863 , C07K2299/00 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/92 , G01N33/5091 , G01N33/57492 , G01N33/74 , A61K2300/00
摘要： The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
摘要翻译：本发明涉及结合EGF受体，特别是与扩增或过表达的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短结合的抗体，特别是抗体175及其衍生的抗体或抗体。这些抗体可用于诊断和治疗癌症。还提供了具有抗体175的可变区重链或轻链序列的重组或杂合抗体。本发明的抗体也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

10. 发明申请

WO2005081854A2 EGF RECEPTOR EPITOPE PEPTIDES AND USES THEREOF 审中-公开
标题翻译： EGF受体EPITOPE PEPTIDES及其用途
公开(公告)号：WO2005081854A2
公开(公告)日：2005-09-09
申请号：PCT/US2005/005155
申请日：2005-02-18
申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH , JOHNS, Terrance, Grant , SCOTT, Andrew, Mark , BURGESS, Antony, Wilks , OLD, Lloyd, J. , ADAMS, Timothy, E. , WITTRUP, K., Dane , CHAO, Ginger
发明人： JOHNS, Terrance, Grant , SCOTT, Andrew, Mark , BURGESS, Antony, Wilks , OLD, Lloyd, J. , ADAMS, Timothy, E. , WITTRUP, K., Dane , CHAO, Ginger
IPC分类号： A61K39/00 , C07H21/04 , C07K14/705 , C07K14/71 , C12N15/09 , C12P21/06
CPC分类号： C07K14/71 , A61K39/00
摘要： The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
摘要翻译：本发明一般涉及生长因子受体表位肽，特别是EGF家族受体表位肽。本发明还涉及受体肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。本发明还涉及特异性针对受体肽的抗体。还提供了产生免疫应答和治疗肿瘤和癌症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式